Sara Silbert, MD, Gregory A. Yanik, MD, and Andrew G. Shuman, MD
“Living” drugs target specific B-cell malignancy tumor antigens, but cost hundreds of thousands of dollars. Value analysis can help determine whether to offer these customized drugs.
AMA J Ethics. 2019;21(10):E844-851. doi:
10.1001/amajethics.2019.844.
Ava Ferguson Bryan, MD, AM, Elizabeth Yates, MD, MPH, and Neelima Tummala, MD, MSc
The health sector has obligations and ample opportunities to protect health by decreasing waste and motivating more system-wide sustainable clinical practices.
AMA J Ethics. 2022;24(10):E927-933. doi:
10.1001/amajethics.2022.927.
Lee C. Zhao, MD, Gaines Blasdel, Augustus Parker, and Rachel Bluebond-Langner, MD
Tension between realistic goals and unrealistic views about how to achieve them is compounded when patients are eager to revise a prior surgeon’s gender-affirming procedure.
AMA J Ethics. 2023;25(6):E391-397. doi:
10.1001/amajethics.2023.391.
Annika Brakebill, A. Mark Fendrick, MD, and Jeffrey T. Kullgren, MD, MS, MPH
These key steps are ones health sector stakeholders should take to help patients and clinicians use pricing information to inform health decision making.
AMA J Ethics. 2022;24(11):E1034-1039. doi:
10.1001/amajethics.2022.1034.
Jing Li, PhD, Robert Tyler Braun, PhD, Sophia Kakarala, and Holly G. Prigerson, PhD
For dying patients and their loved ones to make informed decisions, physicians must share adequate information about prognoses, prospective benefits and harms of specific interventions, and costs.
AMA J Ethics. 2022;24(11):E1040-1048. doi:
10.1001/amajethics.2022.1040.
When confidential medical information can prevent a serious harm to a third party, the patient’s prima facie right to confidentiality must be balanced against the physician’s prima facie obligation to prevent serious harm to that third party.
AMA J Ethics. 2015;17(9):819-825. doi:
10.1001/journalofethics.2015.17.9.ecas1-1509.